Evidence map›Paper›PMID 36764470›Full record

ArticleBioorganic & medicinal chemistry letters2023

Synthesis and biological evaluation of new β-D-N

Yeon Jin An, Se Myeong Choi, Eun Rang Choi, Ye Eun Nam, Eun Woo Seo, Soo Bin Ahn, Yejin Jang, Meehyein Kim, Jong Hyun Cho

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06917001 (A Randomized, Double-blind, Placebo-controled, Phase 2a Trial Evaluating the Safety and Initial Efficacy of Resomelagon in Patients With Dengue Infection), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06917001 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized, Double-blind, Placebo-controled, Phase 2a Trial Evaluating the Safety and Initial Efficacy of Resomelagon in Patients With Dengue Infection

TypeinterventionalSponsorFederal University of Minas GeraisRan2026 to 2027Enrolled120ConditionsDengue FeverArmsResomelagon, Placebo, Standard Treatment
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yeon Jin AnDepartment of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan 49315, South Korea.
Se Myeong ChoiDepartment of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan 49315, South Korea.
Eun Rang ChoiDepartment of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan 49315, South Korea.
Ye Eun NamDepartment of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan 49315, South Korea.
Eun Woo SeoDepartment of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan 49315, South Korea.
Soo Bin AhnInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, South Korea; Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, South Korea.
Yejin JangInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, South Korea.
Meehyein KimInfectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, South Korea; Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, South Korea. Electronic address: mkim@krict.re.kr.
Jong Hyun ChoDepartment of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan 49315, South Korea; Department of Translational Biomedical Sciences, Graduate School of Dong-A University, Busan 49201, South Korea. Electronic address: jhcho1@dau.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug repurposing approach was applied to find a potent antiviral agent against RNA viruses such as SARS-CoV-2, influenza viruses and dengue virus with a concise strategy of small change in parent molecular structure. For this purpose, β-D-N

Indexed as

COVID-19Influenza A Virus, H1N1 SubtypeAntiviral AgentsCytidineHumansHydroxylaminesInfluenza A Virus, H3N2 SubtypeSARS-CoV-2Virus ReplicationAntiviral AgentsCytidineHydroxylaminesmolnupiravirN(4)-hydroxycytidineDENV-2Influenza virusesNucleosidesRNA-PolymeraseSARS-CoV-2β-D-N(4)-Hydroxycytidineβ-D-N(4)-O-Isobutyrylcytidine

Identifiers

PMID36764470
PMCPMC9905048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.